<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NOVOBIOCIN SODIUM</span><br/>(noe-voe-bye'o-sin)<br/><span class="topboxtradename">Albamycin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Antibiotic obtained from cultures of <i>Streptomyces niveus</i> or <i>Streptomyces sphaeroides.</i> Bacteriostatic action appears to involve interference with synthesis of bacterial cell wall and inhibition of bacterial protein
         and nucleic acid synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active in vitro against many gram-positive bacteria including <i>Staphylococcus aureus, Streptococcus pneumoniae,</i> Group A <i>streptococci, viridans streptococci,</i> and against some gram-positive bacilli. <i>Enterococci</i> are usually resistant to novobiocin. Also active against gram-negative bacteria including <i>Haemophilus influenzae</i> and <i>Neisseria gonorrhoeae.</i> Resistant strains of <i>S. aureus</i> may develop rapidly during therapy.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Serious infections due to <i>S. aureus</i> in patients unresponsive to less toxic antibiotics or not sensitive to other antibiotics.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Neonates; during pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver dysfunction.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">
<i>S. aureus</i> Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg q6h or 500 mg q12h up to 2 g/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1545 mg/kg/d in 24 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug at correct time intervals (i.e., q6h or q12h) to ensure effectiveness.</li>
<li>Schedule the two drugs at least 3 h apart when novobiocin is given concurrently with <small>TETRACYCLINES</small>.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea, anorexia, abdominal distress,</span> jaundice, elevated serum bilirubin. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Pancytopenia, agranulocytosis,</span> anemia, thrombocytopenia, hemolytic anemia. <span class="typehead"> Skin:</span>
<span class="speceff-common">Urticaria,</span> maculopapular dermatitis, <span class="speceff-life">Stevens-Johnson syndrome</span>, erythema multiforme, pruritus, eosinophilia. <span class="typehead">Body as a Whole:</span> Dizziness, drowsiness, light-headedness, swollen joints, fever. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>A yellow metabolite may appear if serum interferes with <span class="alt">serum bilirubin</span> determinations <span class="alt">(Evelyn-Malloy method)</span>.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">tetracyclines</span> may reduce novobiocin effectiveness. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 14 h. <span class="typehead">Distribution:</span> Highest concentrations in liver, small intestine, and bile; distributed into breast milk. <span class="typehead">Elimination:</span> Excreted primarily in bile and feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Report adverse effects promptly; this drug is an extremely potent sensitizing agent.</li>
<li>Be aware that a yellow metabolite of novobiocin can cause jaundice-like skin coloration. Differentiation of drug-induced effect
            from frank jaundice will depend on other signs of liver dysfunction (i.e., dark urine, pruritus, elevated serum bilirubin).
            Advise patient to report symptoms promptly.
         </li>
<li>Lab tests: CBC with differential, platelet count, Hct and Hgb, liver function tests at the first sign of an adverse response.</li>
<li>Inspect skin for signs of thrombocyte dyscrasia: petechiae, ecchymoses, easy bruising. Promptly report these signs or epistaxis
            or bleeding for unexplained reason.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any reversal in prior evidence of therapeutic response to drug therapy. Drug resistance may develop rapidly.</li>
<li>Do not stop treatment just because you feel better. Duration of therapy depends on the infection but it will continue about
            48 h after your fever is gone or there is no more evidence of the infection.
         </li>
<li>Do not change your treatment regimen without consulting physician; sensitivity and adverse effects may occur as well as a
            loss of therapeutic effects.
         </li>
<li>Do not use leftover novobiocin to self-medicate for another infection.</li>
<li>Report symptoms of superinfections (see Appendix F) immediately because they should receive prompt attention.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>